Genome-wide association study in Chinese identifies novel loci for blood pressure and hypertension

Xiangfeng Lu1,3,†, Laiyuan Wang1,4,†, Xu Lin5,†, Jianfeng Huang2,3,†, C. Charles Gu6, Meian He7, Hongbing Shen8,9,10, Jiang He11, Jingwen Zhu5, Huaixing Li6, James E. Hixson12, Tangchun Wu7, Juncheng Dai8,9,10, Ling Lu5, Chong Shen8,9, Shufeng Chen1,3, Lin He13, Zengnan Mo14, Yongchen Hao1,3, Xingbo Mo1,3, Xueli Yang1,3, Jianxin Li1,3, Jie Cao1,3, Jichun Chen1,3, Zhongjie Fan15, Ying Li1,3, Liancheng Zhao1,3, Hongfan Li4, Fanghong Lu16, Cailiang Yao9, Lin Yu17, Lihua Xu18, Jianjun Mu19, Xianping Wu20, Ying Deng20, Dongsheng Hu21,22, Weidong Zhang21, Xu Ji23, Dongshuang Guo24, Zhirong Guo25, Zhengyuan Zhou26, Zili Yang27, Renping Wang28, Jun Yang29, Xiaoyang Zhou30, Weili Yan31, Ningling Sun32, Pingjin Gao33 and Dongfeng Gu1,3,∗

1State Key Laboratory of Cardiovascular Disease, 2Hypertension Division, and 3Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China, 4National Human Genome Center at Beijing, Beijing 100176, China, 5Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Graduate School of the Chinese Academy of Sciences, Shanghai 200031, China, 6Division of Biostatistics, Washington University School of Medicine, St. Louis, MO 63110, USA, 7MOE Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China, 8Department of Epidemiology and Biostatistics, Ministry of Education Key Lab for Modern Toxicology, 9School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China, 10Section of Clinical Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing, Jiangsu 210029, China, 11Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA 70112, USA, 12Department of Epidemiology, University of Texas School of Public Health, Houston, TX 77025, USA, 13Bio-X Institutes, Ministry of Education Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Shanghai Jiao Tong University, Shanghai 200030, China, 14Center for Genomic and Personalized Medicine, Medical Scientific Research Center and Department of Occupational Health and Environmental Health, School of Public Health, Guangxi Medical University, Nanning, Guangxi 530021, China, 15Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China, 16Cardio-Cerebrovascular Control and Research Center, Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong 250062, China, 17Department of Cardiology, Fujian Provincial People's Hospital, Fuzhou, Fujian 350004, China, 18Department of Cardiology, Affiliated Hospital of Beihua University, Beihua University, Jilin 132011, China, 19Department of Cardiology, First Affiliated Hospital of Medical College, Xi’an Jiaotong University, Xi’an, Shaanxi 710061, China, 20Center for Chronic and Noncommunicable Disease Control and Prevention, Sichuan Center of Disease Control and Prevention, Chengdu, Sichuan 610041, China, 21School of Public Health, Zhengzhou University, Henan 450001, China, 22School of Medicine, Shenzhen University, Shenzhen, Guangdong 518000, China, 23Department of Internal Medicine, Xinxin Red Cross Hospital, Xiamen, Hebei 050700, China, 24Department of Internal Medicine, Xuyang Renmin Hospital, Xuxian, Shanxi 045100, China, 25Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, Jiangsu 215123, China, 26Changshu Center of Disease Control and Prevention, Changshu, Jiangsu 215501, China, 27Nantong Center of Disease Control and Prevention, Nantong, Jiangsu 226007, China.

†The authors contributed equally to this work.

∗To whom correspondence should be addressed at: State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, China; Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. Tel: +86 1068331752; Fax: +86 10 88363812; Email: gudongfeng@vip.sina.com

© The Author 2014. Published by Oxford University Press. All rights reserved.
For Permissions, please email: journals.permissions@oup.com

doi:10.1093/hmg/ddu478
Advance Access published on September 23, 2014
Hypertension is a common disorder and the leading risk factor for cardiovascular disease and premature deaths worldwide. Genome-wide association studies (GWASs) in the European population have identified multiple chromosomal regions associated with blood pressure, and the identified loci altogether explain only a small fraction of the variance for blood pressure. The differences in environmental exposures and genetic background between Chinese and European populations might suggest potential different pathways of blood pressure regulation. To identify novel genetic variants affecting blood pressure variation, we conducted a meta-analysis of GWASs of blood pressure and hypertension in 11,816 subjects followed by replication studies including 69,146 additional individuals. We identified genome-wide significant ($P < 5.0 \times 10^{-8}$) associations with blood pressure, which included variants at three new loci ($CACNA1D$, $CYP21A2$, and $MED13L$) and a newly discovered variant near $SLC4A7$. We also replicated 14 previously reported loci, $8$ ($CASZ1$, $MOV10$, $FGF5$, $CYP17A1$, $SOX6$, $ATP2B1$, $ALDH2$, and $JAG1$) at genome-wide significance, and $6$ ($FIGN$, $ULK4$, $GUCY1A3$, $HFE$, $TBX3-TBX5$, and $TBX3$) at a suggestive level of $P = 1.81 \times 10^{-3}$ to $5.16 \times 10^{-8}$. These findings provide new mechanistic insights into the regulation of blood pressure and potential targets for treatments.

INTRODUCTION

Hypertension is a common disorder and the leading risk factor for cardiovascular disease and premature deaths worldwide (1). It is a highly heritable trait, and around 40–60% of the inter-individual variation in hypertension is attributable to genetic factors (2). Genome-wide association studies (GWASs) have identified multiple genetic loci associated with blood pressure (3–7). However, the vast majority of these loci were identified in European ancestry populations, and few such genetic studies have assessed Asian populations, especially Chinese populations. Moreover, the identified loci altogether explain only a small fraction of the risk for hypertension (3). Lifestyle factors, including sodium intake, excess alcohol drinking, elevated body mass index (BMI), and lack of exercise, are known to increase blood pressure (8). The differences in environmental exposures and genetic background between Chinese and European populations might suggest potential different pathways of blood pressure regulation. Therefore, large scale studies in Chinese are needed not only to evaluate whether the previous reported loci could be generalized to the Chinese population, but also to identify new susceptibility loci for blood pressure.

Here, we conducted a large scale GWAS of blood pressure and hypertension that included a meta-analysis of GWAS from 11,816 samples at the discovery stage and additional 69,146 samples in three independent replication studies, involving a total of 80,962 subjects from Chinese Han ancestry. We subsequently investigated whether the blood pressure variants would contribute to the traditional cardiovascular risk factors including lipid levels, plasma glucose, and BMI.

RESULTS

The discovery and replication study

The discovery stage included six independent GWASs in 11,816 individuals from Chinese populations (Table 1). The discovery meta-analysis separately evaluated associations for systolic and diastolic blood pressure (SBP and DBP) and hypertension, with 2,485,448 genotyped or imputed autosomal single-nucleotide polymorphisms (SNPs). All genotyped and imputed autosomal SNPs passed quality control filters in each of the six datasets prior to conducting the meta-analysis (Supplementary Material, Table S1). Quantile–quantile plots for SBP, DBP, and hypertension are presented in Supplementary Material, Figure S1. The genomic control inflation factor ($\lambda$) for the meta-analysis was modest ($\lambda = 1.04$), indicating that population stratification effects were negligible in our study samples. As shown in the Manhattan plots of the $-\log_{10}$ $P$-values for SBP, DBP, and hypertension in Supplementary Material, Figure S2, the meta-analysis identified two well-established loci ($FGF5$ and $CYP17A1$) at genome-wide significance (defined as $P < 5.0 \times 10^{-8}$).

We then selected 15 new SNPs that were associated with blood pressure at $P < 1.0 \times 10^{-3}$ and 24 SNPs located in previously reported loci at $P < 5.0 \times 10^{-3}$ in the discovery analysis (see Materials and Methods and Supplementary Material, Fig. S3) and genotyped them in the first replication study comprising 12,108 Chinese individuals (replication 1). Twenty-two SNPs showed nominal significant association ($P < 0.05$) with SBP, DBP, and/or hypertension in the replication 1 and were further genotyped in an independent sample of 22,896 individuals (replication 2). Of these 22 SNPs, 14 SNPs represented the replication of previously reported associations with blood
pressure, while the remaining 8 SNPs were located in novel regions for blood pressure or independent of the reported association. The detailed results for each study were provided in Supplementary Material, Table S2. We evaluated the evidence of association by combined results of the discovery, replication 1, and replication 2 studies.

**Associations at loci previously identified by GWAS**

Our Chinese samples replicated 14 loci previously identified in GWAS in European descent or East Asians at various strengths of associations [**SOX6** was initially identified using gene-centric array (9, 10), and confirmed by GWAS in African-Ancestry individuals (7)] (Table 2). Those included eight loci (**CASZ1**, **MOY10**, **FGF5**, **CYP17A1**, **SOX6**, **ATP2B1**, **ALDH2**, and **JAG1**) at the level of genome-wide significance (**P < 5.0 × 10⁻⁸**), four loci (**ULK4**, **GUCY1A3**, **HFE**, and **TBX3**) with suggestive significance (**P < 5.0 × 10⁻⁶**), and two loci (**FIGN** and **TBX3-TBX5**) at a less significant level of **P < 5.0 × 10⁻⁵**.

**New blood pressure loci and Chinese-specific variants**

The meta-analysis of the discovery and replication 1 and replication 2 studies found four novel regions for blood pressure. Among them, rs9810888 at the **CACNA1D** locus, rs2021783 at **CYP21A2**, and rs11067763 at **MED13L** achieved genome-wide significance (**P < 5.0 × 10⁻⁸**), while rs9266359 at the **HLA-B** locus showed nominal significance (**P < 0.05**). After meta-analysis combining results of the discovery and all three replication studies, we identified three new blood pressure loci (Fig. 1). These include SNPs at 3p21.1 in **CACNA1D** (DBP, **P = 4.00 × 10⁻¹²**), 6p21.32 near **CYP21A2** (SBP, **P = 3.19 × 10⁻⁹**; DBP, **P = 2.18 × 10⁻¹²**; hypertension, **P = 3.53 × 10⁻¹¹**), and 12q24.21 near **MED13L** (SBP, **P = 5.68 × 10⁻¹⁶**; DBP, **P = 2.00 × 10⁻¹⁸**) (Table 2). We also detected a Chinese-specific variant in previous reported regions in European populations [rs820430 at 3p21.1 near **SLC4A7** (SBP, **P = 1.36 × 10⁻¹²**)]. The reported lead SNP rs13082711 at **SLC4A7** associated with blood pressure in Europeans had low minor allele frequency (MAF = 0.05) in the Chinese Han population. The SNP rs820430 in Europeans and rs820430 identified in this study are not in LD (**r² = 0.06** in HapMap JPT + CHB) (Supplementary Material, Fig. S4). In addition, the SNP rs9266359 at **HLA-B** reached the near-genome-wide significance of **P = 1.76 × 10⁻⁷**, and by the consistent evidences showing the same direction of association across the discovery and all replication studies. There was no evidence of between-study heterogeneity of effect-size estimates for all these new variants (all **P > 0.11**; **I² ≤ 41%**; Supplementary Material, Table S3).

**Pleiotropic effects of blood pressure loci on established cardiovascular risk factors**

To gain further understanding of the blood pressure susceptibility loci identified and validated in the Chinese population summarized in Table 2, we tested their associations with lipid levels, plasma glucose, and BMI in the replication samples. After Bonferroni correction for 19 independent tests, three loci...
Table 2. Blood pressure and hypertension susceptibility loci identified by GWAS in the Chinese

<table>
<thead>
<tr>
<th>Nearby gene</th>
<th>SNP</th>
<th>CHR</th>
<th>Position</th>
<th>Risk/no. of risk allele</th>
<th>n</th>
<th>RAF</th>
<th>SBP (S.E.)</th>
<th>P-value</th>
<th>DBP (S.E.)</th>
<th>P-value</th>
<th>HTN (S.E.)</th>
<th>P-value</th>
<th>Previously reported trait(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CACNA1D</td>
<td>rs9810888</td>
<td>3</td>
<td>53 610 635 G/T</td>
<td>77 555</td>
<td>0.39</td>
<td>0.53 (0.10)</td>
<td>5.46 × 10^{-8}</td>
<td>0.39 (0.06)</td>
<td>4.00 × 10^{-12}</td>
<td>0.056 (0.012)</td>
<td>3.60 × 10^{-6}</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>CYP21A2</td>
<td>rs2021783</td>
<td>6</td>
<td>32 152 829 C/T</td>
<td>78 911</td>
<td>0.79</td>
<td>0.68 (0.12)</td>
<td>3.19 × 10^{-9}</td>
<td>0.49 (0.07)</td>
<td>2.18 × 10^{-12}</td>
<td>0.094 (0.014)</td>
<td>3.53 × 10^{-11}</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>MED13L</td>
<td>rs11067763</td>
<td>12</td>
<td>114 682 724 A/G</td>
<td>79 651</td>
<td>0.62</td>
<td>0.81 (0.10)</td>
<td>5.68 × 10^{-16}</td>
<td>0.51 (0.06)</td>
<td>2.00 × 10^{-18}</td>
<td>0.061 (0.012)</td>
<td>1.37 × 10^{-7}</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>SLC4A7</td>
<td>rs820430</td>
<td>3</td>
<td>27 523 904 A/G</td>
<td>79 318</td>
<td>0.32</td>
<td>0.76 (0.11)</td>
<td>1.36 × 10^{-12}</td>
<td>0.27 (0.06)</td>
<td>7.57 × 10^{-6}</td>
<td>0.059 (0.012)</td>
<td>1.12 × 10^{-6}</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>HLA-B</td>
<td>rs9266359</td>
<td>6</td>
<td>31 440 718 C/T</td>
<td>78 365</td>
<td>0.60</td>
<td>0.44 (0.10)</td>
<td>7.07 × 10^{-6}</td>
<td>0.29 (0.06)</td>
<td>1.76 × 10^{-7}</td>
<td>0.050 (0.012)</td>
<td>1.33 × 10^{-5}</td>
<td>–</td>
<td></td>
</tr>
</tbody>
</table>

SNP IDs and chromosomal positions are based on NCBI Build 36 of the genome.
CHR, chromosome; RAF, risk allele frequency.
Effect size estimates (β) correspond to mmHg per risk allele for SBP and DBP, and log(odds) per risk allele for hypertension (HTN).
showed significant associations ($P < 2.6 \times 10^{-3} \approx 0.05/19$) with plasma lipid traits in the expected direction (the blood pressure risk allele at CYP21A2 was associated with higher total cholesterol concentrations, at ALDH2 with higher triglyceride concentrations, and at CASZ1 with lower high-density lipoprotein cholesterol concentration; Supplementary Material, Table S4). Similarly, significant associations with BMI ($P < 2.6 \times 10^{-3}$) were observed in the six loci (FIGN, SLC4A7, CYP21A2, HLA-B, CYP17A1, and ALDH2). Except for FIGN and CYP17A1, the risk alleles were associated with increased BMI in a direction consistent with their associations with high blood pressure risk. Of note, the association of ALDH2 with BMI reached genome-wide significance ($P = 1.21 \times 10^{-15}$), which represented an unreported locus for BMI.

**Cumulative impact of risk alleles on blood pressure and hypertension**

Weighted risk scores incorporating the 19 variants (Table 2) were calculated to examine the aggregate effect of risk alleles on blood pressure levels and risk of hypertension. Blood pressure levels increased linearly with an increase of weighted risk scores...
Regression estimates of slope (β) and its standard error (S.E.) were obtained across risk score groups for blood pressure levels. The null hypothesis of a zero slope across risk score groups was tested using two-tailed P-values [from $Z = \beta / S.E. (\beta)$]. The P-values for slope across risk score groups were $4.73 \times 10^{-67}$ for SBP and $2.03 \times 10^{-69}$ for DBP. Logistic regression models were applied to examine the relationship between weighted risk score and risk of hypertension. Individuals in the top quintile of genotype risk score had a 66% increased risk for hypertension compared with those in the bottom quintile (OR = 1.66, 95% CI = 1.54–1.79; Supplementary Material, Table S5).

**Functional potential of blood pressure loci by expression quantitative trait loci analysis**

To clarify the possible transcriptional mechanisms underlying the identified loci in associations with blood pressure and hypertension, we investigated the relationships of lead SNPs and proxies with expression quantitative trait loci (eQTLs) in lymphoblastoid cell lines (LCLs), adipose, liver, skin, and other tissues. *Cis*-eQTLs effects were found at *CACNA1D* (Supplementary Material, Table S6).

**Pathway analysis**

We applied the Gene Relationships Among Implicated Loci (GRAIL) (11) text-mining algorithm to investigate connections between 19 loci (Table 2). This analysis revealed significant ($P_{GRAIL} < 0.05$) connections among blood pressure-associated genes (Supplementary Material, Fig. S5). We further investigated excessive connectivity between the 19 loci and those loci that showed a level of significance for association ($P < 0.0001$) in the discovery study. The less stringent threshold yielded 177 suggestive regions for blood pressure, among which we observed that 26 genes were connected to the 19 loci at $P_{GRAIL} < 0.05$ (Supplementary Material, Table S7). These included genes such as *FGF14* (fibroblast growth factor 14, $P_{GRAIL} = 4.8 \times 10^{-4}$), *HLA-DPB1* (major histocompatibility complex, class II, DP beta 1, $P_{GRAIL} = 2.0 \times 10^{-3}$), and *SCNNIB* (natriuretic peptide A, $P_{GRAIL} = 9.7 \times 10^{-3}$).

We applied MAGENTA (Meta-Analysis Gene-set Enrichment of variaNT Associations) (12) to detect enrichment of association signals in gene sets compiled from known biological pathways. The MAGENTA analysis implicated 17 biological pathways and molecular functions with a nominal $P$-value of $<0.01$ for SBP, DBP, and/or hypertension (Supplementary Material, Table S8). Most of these gene sets contain genes capturing or near a validated blood pressure SNP. For example, the KEGG MAPK signaling pathway included the newly identified *CACNA1D*.

**DISCUSSION**

This study describes the largest GWAS of blood pressure and hypertension in Chinese to date involving a total of 80,962 individuals. We identified three new loci (*CACNA1D, CYP21A2*, and *MED13L*) and a newly discovered variant near *SLC4A7* at the genome-wide significance level. We also replicated 14 loci previously reported loci, 8 (*CASZ1, MOV10, FGF5, CYP17A1, SOX6, ATP2B1, ALDH2, and JAG1*) at genome-wide significance, and 6 (*FIGN, ULK4, GUCY1A3, HFE, TBX3-TBX5, and TBX3*) at a suggestive level of $P = 1.81 \times 10^{-7}$ to $5.16 \times 10^{-8}$.

The identification of new genes for blood pressure can help further our understanding of new mechanistic insights into the regulation of blood pressure and potential targets for treatments. *CACNA1D* encodes a member of the alpha-1 subunit family of voltage-dependent calcium channels, several of which have effects on blood pressure regulation and serve as targets of calcium channel blockers. More recently, somatic and germline mutations in the *CACNA1D* gene in aldosterone-producing adenomas and primary aldosteronism were identified. These mutations resulted in channel activation at more hyperpolarized membrane potentials, implicating increased Ca$^{2+}$ influx in disease pathogenesis (13). Another calcium channel encoding gene, *CACNB2*, has been reported to be associated with DBP (4). This emphasizes the importance of calcium channels in...
the regulation of blood pressure. CYP21A2 encodes a member of the cytochrome P450 superfamily required for the synthesis of steroid hormones including cortisol and aldosterone. Aldosterone regulates the amount of salt retained by the kidneys, and thus affects blood volume in the body and blood pressure. Mutations in CYP21A2 can cause congenital adrenal hyperplasia (14), a common autosomal recessive disorder caused by deficiency in the steroid 21-hydroxylase. The other two members of the family, CYP17A1 and CYP1A2, were also found associated with blood pressure (5). MED13L encodes a subunit of the mediator complex co-activating RNA polymerase II-induced transcription and is active in peroxisome proliferator-activated receptor alpha-related pathways for fatty acid metabolism that are important to hypertensive heart diseases. Missense mutations of MED13L were associated with transposition of the great arteries (15). It is also involved in Rb/E2F-mediated control of cell growth (16) and to promote proliferation of vascular smooth muscle cells(17), which participate in the progression of hypertension.

Our results showed that both shared and population-specific blood pressure susceptibility were commonly present. Of five new blood pressure variants identified in our Chinese samples, three (CACNA1D, MED13L, and SLC4A7) showed associations at various significance levels (P = 8.66 × 10^{-3} to 4.16 × 10^{-4}) in the International Consortium for Blood Pressure Genome-Wide Association Studies (ICBP) (Supplementary Material, Table S9). For the remaining two SNPs, one is monomorphic in Europeans and the other has much difference in risk allele frequency between the two populations. Conversely, of the 34 loci identified in GWAS meta-analysis in individuals of European descent and East Asian, 17 (50%) showed significant associations at various significance levels in Chinese (Supplementary Material, Table S10). Of note, the effect sizes of blood pressure variants differ between the Chinese and European populations. For those loci that were not significant in our Chinese samples, six SNPs were monomorphic or had a low MAF (MAF < 0.05) in the Chinese Han population, suggesting that some of the discrepancies in association between the European and Chinese populations may be due to different LD structure. Therefore, studies conducted in Chinese populations, in addition to allowing an evaluation of the extent to which genetic markers of blood pressure identified in European populations can be generalized, also might lead to the identification of new blood pressure-associated loci.

We successfully identified new blood pressure loci by testing SNPs with P < 1.0 × 10^{-5} in the discovery meta-analysis. However, many blood pressure risk alleles with small-to-modest effects will still be missed at that significance threshold. We expected that some true disease loci at P < 0.0001 might share the same pathways with those detected at the genome-wide significance, and as such, could be detected through their connections with the 19 genome-wide significant loci. We found 26 such loci with a significant degree of functional connectivity at PGRAIL < 0.05 (Supplementary Material, Table S7). Besides, MAGENTA analysis identified suggestive pathways, some of which contained genes at validated blood pressure loci. These findings likely represent true associations and novel pathways, but additional studies will be necessary for definitive confirmation.

Our results should be interpreted in the context of potential limitations. First, our discovery sample size is not large enough compared with those in the previous consortia of European descent (3–5). This means that some signals especially with a low MAF and/or weaker genetic effects would not be initially detected in our study. Secondly, we adjusted for use of antihypertensive therapy by adding 10 and 5 mmHg for SBP and DBP, respectively. This approach is relatively simple and widely adopted. However, it is noteworthy that despite increased rates of blood pressure lowering treatment, few have their hypertension effectively controlled in China (18, 19). We have addressed this issue by performing a sensitivity analysis and verified that our results were not substantially modified by blood pressure adjustment or no adjustment (Supplementary Material, Table S11).

In conclusion, we identified previously unreported association signals for blood pressure (CACNA1D, CYP21A2, and MED13L). Near SLC4A7, we also identified some evidence for allelic heterogeneity in Chinese compared with Europeans in relation to blood pressure associations. We replicated 14 previously reported loci in the Chinese samples. Increasing efforts in conducting the studies in multiple diverse populations will be critical for better understanding of the genetic architecture of blood pressure.

MATERIALS AND METHODS

Study design and population

A detailed description of the sample characteristics and phenotype measurements for each study are provided in Table 1 and Supplementary Material, Methods. The discovery stage was a meta-analysis consisted of 11,816 Han Chinese who underwent standardized collection of blood pressure measurements in six GWASs. These studies, named the Genetic Epidemiology Network of Cardiovascular Disease in China (GENE CDC), included the International Collaborative Study of Cardiovascular Disease in Asia (InterASIA in China) (20), Beijing Cardiovascular Risk Factors study (Beijing) (21), Genetic Epidemiology Network of Salt-Sensitivity study (GenSalt) (22), the Nutrition and Health of Aging Population in China (NHAPC) (23), Non-communicable Diseases Screening study in Nanjing (Nanjing) (24), and the Dongfeng-Tongji cohort (DFTJ) study (25). Three blood pressure measurements were measured by using standard mercury sphygmomanometer or electronic BP monitor. For individuals who were taking antihypertensive medication, blood pressure was imputed by adding 10 and 5 mmHg for SBP and DBP, respectively. Hypertension was defined by the presence of SBP ≥ 140 mmHg or DBP ≥ 90 mmHg, or self-reported of taking a medication for the treatment of hypertension. Normotensive controls were defined as individuals not taking any antihypertensives and having a SBP of < 140 mmHg and a DBP of < 90 mmHg.

Each study obtained approval from the institutional review boards of Fuwai Hospital, the Chinese Academy of Medical Sciences and Peking Union Medical College, and other medical institutions. All participants gave written informed consent.

Genotype imputation

Detailed descriptions of genotyping arrays and quality control filters applied to the six discovery studies are provided in Supplementary Material, Table S1. To facilitate combining results of genome-wide association scans based on the different
Selection of replication SNPs and genotyping

After genome-wide association analyses for each of the six discovery studies and meta-analysis in the combined sample, SNPs representing the independent association signal were taken forward to replication 1 if they (i) showed potential association ($P < 1.0 \times 10^{-5}$) for SBP, DBP, or/and hypertension in the discovery meta-analysis; (ii) associated at $P < 5.0 \times 10^{-3}$ in the meta-analysis discovery stage in a locus previously reported to show association with genome-wide significance. If a SNP could not be genotyped, alternative tagging SNPs (with $r^2$ of >0.8) were considered. In total, 39 SNPs were selected and genotyped using the iPLEX Sequenom MassARRAY platform (Sequenom) for replication 1. Considering that replication 1 sample has ~80% power to detect a common SNP with an effect size of 1 mmHg for SBP or 0.5 mmHg for DBP using a $P$-value threshold of 0.05, we selected potential significant SNPs by the conservative criterion ($P < 0.05$) and further genotyped them in replication 2 using the iPLEX MassARRAY platform. To assess genotyping reproducibility, 380 duplicate samples were genotyped, and the concordance rate was determined to be >99.8%. We sought further evidence for association with eight SNPs in replication 3 using the TaqMan genotyping platform (ABI 7900HT Real Time PCR system, Applied Biosystems). To evaluate the quality of the genotype data between different genotyping platforms, eight SNPs in 96 random replication samples genotyped on the iPLEX Sequenom MassARRAY platform were also genotyped on the TaqMan genotyping platform, and the concordance rate between the genotypes from the two platforms was found to be 99.7%. Cluster patterns of genotyping data from the Sequenom and TaqMan analyses were examined to confirm high quality.

Statistical analysis

Within each of the six discovery studies, continuous SBP and DBP were adjusted for age, age-squared, gender, and BMI in linear regression models under an additive model, using the software as specified in Supplementary Material, Table S1. Analysis of hypertension was conducted within four studies (InterASIA, NHAPC, Nanjing, and DFTJ). Within each study, logistic regression was fitted for hypertension, adjusting for sex, age, age-squared, and BMI. We used allele dosages from imputation to account for uncertainty in imputed genotypes. A fixed-effects inverse variance-weighted meta-analysis implemented in METAL (28) was used to combine the six studies in discovery stage and to obtain results for each SNP. A quantile–quantile plot generated using R was used to evaluate the overall significance of the GWAS results and the potential impact of population stratification. The genomic inflation factor ($\lambda$) was estimated from the median of the $\chi^2$ statistic divided by 0.456. We detected the associations of SNPs in the replication populations, and additionally, we carried out meta-analysis of the discovery and replications results and considered associations genome-wide significant if they attained $P < 5.0 \times 10^{-8}$.

Associations of loci with established cardiovascular risk factors were examined in replication 1, 2, and 3 (if applicable) samples. High-density lipoprotein, low-density lipoprotein, total cholesterol, triglycerides (naturally logarithm transformed), fasting plasma glucose, and BMI were adjusted for age and gender in linear regression models with an additive model (1 d.f.) We combined the regression estimates from each study in a meta-analysis using inverse variance weighting.

Assessment of cumulative effect of risk variants

Blood pressure risk scores incorporating the associated SNPs were calculated for individuals in replication 1 and 2 samples. The doses of risk alleles were weighted by their effect sizes based on all discovery and replication meta-analyses and summed for each individual to calculate risk score. A risk score was rounded to 1 mmHg for SBP (groups ≤12 to ≥22) and 0.5 mmHg for DBP (groups ≤6.5 to ≥12). For SBP and DBP, we estimated the mean blood pressure level and standard error within each risk score group. For hypertension, odds ratio was calculated using a logistic regression model, with the reference group being those with weighted hypertension risk score of bottom quintile.

eQTL analysis

For each of our newly discovered loci, all proxies ($r^2 > 0.8$) were identified using data from HapMap CHB + JPT (release 23). cis-eQTL (defined as genes within 1 Mb) of lead SNP and their proxies were investigated in public databases including the following tissues and cell lines: liver (29), four brain regions (cerebellum, frontal cortex, temporal cortex, and pons) (30), LCL (31–35), adipose (32, 35), skin (32, 35), fibroblast (34), and T-cell (34). For each transcript associated with a lead blood pressure SNP or proxy, the lead cis-eQTL SNP was further identified and then LD between them was estimated using the HapMap CHB + JPT data.

Text-mining and pathway analysis

We used GRAIL (11) to evaluate whether loci associated with blood pressure were enriched for connectivity between genes representing particular pathways or molecular processes. GRAIL is a text-mining tool that identifies non-random, evidence-based links between genes using PubMed abstracts. Genes are given a significance score. PubMed abstracts published after December 2006 were omitted from the analysis to reduce confounding by results from GWAS. We performed two analyses. First, we took 19 loci (Table 2) as a seed and queried loci to investigate biological connectivity among these loci. Secondly, we investigated connectivity between the 19 loci (as seed regions) and those that were suggestively associated with SBP, DBP, and/or hypertension ($P < 0.0001$) (as query regions). Query regions were defined by taking all SNPs more significant than $P < 0.0001$, removing those at the 19 loci and pruning SNPs of $r^2 > 0.2$ in each region using PLINK. As GRAIL tests the connectivity of regions, we also removed any
duplicates where a region was represented by more than one SNP. This approach identified 177 query regions (representing 401 genes).

We tested whether the overall genome-wide association results were enriched in gene sets derived from known biological pathways using MAGENTA (12). MAGENTA calculates a corrected gene association P-value based on the most significant SNP association P-value of all SNPs in the gene region (110 kb upstream and 40 kb downstream of the gene’s most extreme transcript boundaries), accounting for gene size, number of SNPs/gene, and recombination. Pathway terms from five databases within MAGENTA v2.4 (KEGG (June 2008), Panther Signaling Pathways (June 2008), PANTHER Biological Processes (January 2010), PANTHER Molecular Function (January 2010), and Ingenuity Pathway (June 2008)) were attached to each gene. For each pathway, enrichment of highly ranked gene scores above the given significance threshold (95th percentile of all gene scores) was evaluated. This statistic is then compared with 10 000 randomly permuted gene sets of identical size from the genome. Analysis was performed for the discovery meta-analysis results for SBP, DBP, and hypertension.

WEB RESOURCES

SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.

ACKNOWLEDGEMENTS
The authors acknowledge the role of the Genetic Epidemiology Network of Cardiovascular Disease in China (GENECDC) in developing this manuscript. GENECDC members include the International Collaborative Study of Cardiovascular Disease in Asia (InterASIA in China), Beijing Cardiovascular Risk Factors study (Beijing), Genetic Epidemiology Network of Salt-Sensitivity study (GenSalt), The Nutrition and Health of Aging Population in China (NHAPC), Noncommunicable Diseases Screening study in Nanjing (Nanjing), and Dongfeng-Tongji Cohort Study (DFTJ). We also thank the ICBP Consortium for providing online blood pressure association results.

Conflict of Interest statement. None declared.

FUNDING
This study was funded by the High-Tech Research and Development Program of China (863 Plan; 2012AA02A516 and 2009AA022703) and the National Basic Research Program of China (973 Plan; 2011CB503901) from the Ministry of Science and Technology of China. InterASIA was funded by the National Science Foundation of China (30930047) and grants (2011BA111B03) from the Ministry of Science and Technology of China. Beijing was funded by the High-Tech Research and Development Program of China (863 Plan; 2006AA02A406) and Biomedical Project from the Council of Science and Technology, Beijing (H020220030130). GenSalt was supported by research grants (U01HL072507, R01HL 087263, and R01HL090682) from the National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, Maryland, USA). NHAPC was supported by the National High Technology Research and Development Program (863 Program; 2009AA022704), the National Basic Research Program of China (973 Program; 2012CB524900), the National Natural Science Foundation of China (30930081, 81170734, and 81021002), the Chinese Academy of Sciences (KSCX2-EW-R-10 and SIBS200806), and Key Discipline of Shanghai Public Health-Food and Nutritional Sciences (12GWZX0702). Nanjing was funded by the China National High-Tech Research and Development Program Grant (2009AA022705), the National Natural Science Foundation of China (81273165), and the National Science Foundation of Jiangsu Province (BK2011776). DFTJ was supported by grants from the National Basic Research Program Grant (2011CB503806) and the Program of Introducing Talents of Discipline to Universities to T. Wu and Program for New Century Excellent Talents in University and the National Natural Science Foundation of China (81172751) to M.H. CCHS was funded by the grants (2011BA111B03 and 2011BA109B03) from the Ministry of Science and Technology of China.

REFERENCES


